Danish labtech startup Reshape has successfully secured $20 million in a Series A funding round led by Astanor Ventures and saw participation from notable investors such as Y Combinator, R7, ACME, 21stBio, and Nicholas Francis, the co-founder of Unity.
The newly raised funds will primarily support Reshape’s expansion into the United States market and aid in attracting top talent to further enhance their offerings.
Reshape Biotech specializes in developing a new generation of lab automation robots and the accompanying infrastructure to enhance the efficiency and productivity of scientists and technicians. Their goal is to leverage automation and digitization to accelerate experimentation processes and facilitate cross-disciplinary collaboration on a global scale.
The company’s robots incorporate advanced technologies such as mechatronics, cloud computing, machine learning-based data analysis, and a deep understanding of biotech applications. These vertically integrated robots streamline data capture and analysis, eliminating redundant processes and enabling customers to digitize microbiology experiments effortlessly.
Reshape’s technology transforms the traditionally slow and error-prone biological analysis process into a precise and scalable operation. By automating manual tasks, their solutions save customers over 500,000 hours annually, allowing researchers to focus more on innovation and discovery.
According to Carl-Emil Grøn, CEO & Co-Founder of Reshape, the funding is not only about improving efficiency but also about accelerating scientific breakthroughs to address global challenges effectively.
